Literature DB >> 29321659

Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

Zhenyi An1, Ozlem Aksoy1, Tina Zheng1, Qi-Wen Fan1, William A Weiss2,3,4.   

Abstract

Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors (TKIs) or antibodies has only shown limited efficacy in patients. Here we discuss signaling pathways mediated by EGFR/EGFRvIII, current therapeutics, and novel strategies to target EGFR/EGFRvIII-amplified GBM.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29321659      PMCID： PMC5860944          DOI： 10.1038/s41388-017-0045-7

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


  149 in total

1.  EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.

Authors:  Gianmaria Liccardi; John A Hartley; Daniel Hochhauser
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

Review 2.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

3.  De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.

Authors:  David Akhavan; Alexandra L Pourzia; Alex A Nourian; Kevin J Williams; David Nathanson; Ivan Babic; Genaro R Villa; Kazuhiro Tanaka; Ali Nael; Huijun Yang; Julie Dang; Harry V Vinters; William H Yong; Mitchell Flagg; Fuyuhiko Tamanoi; Takashi Sasayama; C David James; Harley I Kornblum; Tim F Cloughesy; Webster K Cavenee; Steven J Bensinger; Paul S Mischel
Journal:  Cancer Discov       Date:  2013-03-26       Impact factor: 39.397

Review 4.  Ligand-Independent EGFR Signaling.

Authors:  Gao Guo; Ke Gong; Bryan Wohlfeld; Kimmo J Hatanpaa; Dawen Zhao; Amyn A Habib
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

5.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.

Authors:  Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Journal:  Oncogene       Date:  2003-05-08       Impact factor: 9.867

6.  EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.

Authors:  Joshua M Francis; Cheng-Zhong Zhang; Cecile L Maire; Joonil Jung; Veronica E Manzo; Viktor A Adalsteinsson; Heather Homer; Sam Haidar; Brendan Blumenstiel; Chandra Sekhar Pedamallu; Azra H Ligon; J Christopher Love; Matthew Meyerson; Keith L Ligon
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397

7.  EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.

Authors:  Eskil Eskilsson; Gro V Rosland; Krishna M Talasila; Stian Knappskog; Olivier Keunen; Andrea Sottoriva; Sarah Foerster; Gergely Solecki; Torfinn Taxt; Radovan Jirik; Sabrina Fritah; Patrick N Harter; Kristjan Välk; Jubayer Al Hossain; Justin V Joseph; Roza Jahedi; Halala S Saed; Sara G Piccirillo; Inma Spiteri; Lina Leiss; Philipp Euskirchen; Grazia Graziani; Thomas Daubon; Morten Lund-Johansen; Per Øyvind Enger; Frank Winkler; Christoph A Ritter; Simone P Niclou; Colin Watts; Rolf Bjerkvig; Hrvoje Miletic
Journal:  Neuro Oncol       Date:  2016-06-10       Impact factor: 12.300

8.  Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility.

Authors:  Mikkel W Pedersen; Vadim Tkach; Nina Pedersen; Vladimir Berezin; Hans S Poulsen
Journal:  Int J Cancer       Date:  2004-02-20       Impact factor: 7.396

9.  EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.

Authors:  Qi-Wen Fan; Christine K Cheng; W Clay Gustafson; Elizabeth Charron; Petra Zipper; Robyn A Wong; Justin Chen; Jasmine Lau; Christiane Knobbe-Thomsen; Michael Weller; Natalia Jura; Guido Reifenberger; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

10.  Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II.

Authors:  Julie L Boerner; Michelle L Demory; Corinne Silva; Sarah J Parsons
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272
View more
  135 in total

Review 1.  Multiple strategies to improve the therapeutic efficacy of oncolytic herpes simplex virus in the treatment of glioblastoma.

Authors:  Zhengjun Zhou; Junjie Tian; Wenyan Zhang; Wei Xiang; Yang Ming; Ligang Chen; Jie Zhou
Journal:  Oncol Lett       Date:  2021-05-03       Impact factor: 2.967

2.  EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma.

Authors:  Zhenyi An; Christiane B Knobbe-Thomsen; Xiaohua Wan; Qi Wen Fan; Guido Reifenberger; William A Weiss
Journal:  Cancer Res       Date:  2018-11-06       Impact factor: 12.701

3.  Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells.

Authors:  Marienela Buendia Duque; Kelly de Vargas Pinheiro; Amanda Thomaz; Camila Alves da Silva; Natália Hogetop Freire; André Tesainer Brunetto; Gilberto Schwartsmann; Mariane Jaeger; Caroline Brunetto de Farias; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2019-03-18       Impact factor: 3.444

4.  KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma.

Authors:  Michael J Ciesielski; Yahao Bu; Stephan A Munich; Paola Teegarden; Michael P Smolinski; James L Clements; Johnson Y N Lau; David G Hangauer; Robert A Fenstermaker
Journal:  J Neurooncol       Date:  2018-09-20       Impact factor: 4.130

Review 5.  Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Authors:  Mekdem Tesfaye; Barbara Savoldo
Journal:  Curr Oncol Rep       Date:  2018-08-01       Impact factor: 5.075

6.  EGFR/EGFRvIII partly regulates the tumourigenesis of glioblastoma through the SOX9-GLUT3 axis.

Authors:  Shenbo Chen; Liangwang Yang; Zhengzheng Li; Shenghua Zhuo; Bo Yan; Zhaoteng Zhang; Jinben Zhang; Haizhong Feng; Kun Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

7.  'Characterization of monoclonal antibodies generated to the 287-302 amino acid loop of the human epidermal growth factor receptor'.

Authors:  Eric Chun Hei Ho; Antonella Antignani; Robert Sarnovsky; David FitzGerald
Journal:  Antib Ther       Date:  2019-11-29

8.  Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain.

Authors:  Deepto Mozumdar; Amy Doerner; Justin Y Zhang; Diane N Rafizadeh; Alanna Schepartz
Journal:  Biochemistry       Date:  2020-10-05       Impact factor: 3.162

9.  Gefitinib induces EGFR and α5β1 integrin co-endocytosis in glioblastoma cells.

Authors:  Anne-Florence Blandin; Elisabete Cruz Da Silva; Marie-Cécile Mercier; Oleksandr Glushonkov; Pascal Didier; Stéphane Dedieu; Cristophe Schneider; Jessica Devy; Nelly Etienne-Selloum; Monique Dontenwill; Laurence Choulier; Maxime Lehmann
Journal:  Cell Mol Life Sci       Date:  2020-11-05       Impact factor: 9.261

10.  Anti-epidermal growth factor receptor therapy for glioblastoma in adults.

Authors:  Adrian Lee; Malmaruha Arasaratnam; David Lok Hang Chan; Mustafa Khasraw; Viive M Howell; Helen Wheeler
Journal:  Cochrane Database Syst Rev       Date:  2020-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.